COVID-19与疟疾合并感染对临床结局的影响:一项回顾性队列研究
在苏丹喀土穆COVID-19治疗中心,591例确诊COVID-19并检测疟疾的住院患者中,45.7%合并疟疾。合并疟疾患者全因院内死亡风险高于单纯COVID-19患者(HR 1.43,95%CI 1.21-1.69)。
要点
- COVID-19住院患者中疟疾合并感染率为45.7%(270/591)。
- 合并疟疾患者粗死亡率为10.71/1000人日,无疟疾者为5.87/1000人日。
- 完全校正后合并疟疾与更高死亡风险相关(HR 1.43,95%CI 1.21-1.69)。
核心结论
- 与单纯SARS-CoV-2感染相比,COVID-19与疟疾合并感染与更高的全因院内死亡风险相关。
研究设计与样本
- 回顾性队列研究,评估2020年5月至12月苏丹喀土穆Universal COVID-19治疗中心(UCTC)所有住院患者的前瞻性收集数据。
- 纳入591例确诊COVID-19并检测疟疾的患者,以疟疾状态为主要暴露,构建逐步校正年龄、性别、心血管合并症、糖尿病和高血压的比例风险Cox模型。
主要发现
- 平均(SD)年龄58(16.2)岁,446/591(75.5%)为男性。
- 270/591(45.7%)患者诊断疟疾,其中140/270(51.9%)感染恶性疟原虫(Plasmodium falciparum),121/270(44.8%)合并感染恶性疟原虫和间日疟原虫(Plasmodium vivax)。
- 中位随访29天。
- 合并疟疾患者粗死亡率为10.71/1000人日,无合并疟疾者为5.87/1000人日。
- 完全校正Cox模型中,合并疟疾与COVID-19患者死亡风险更高相关(HR 1.43,95%CI 1.21-1.69)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Despite the possibility of concurrent infection with COVID-19 and malaria, little is known about the clinical course of coinfected patients. We analysed the clinical outcomes of patients with concurrent COVID-19 and malaria infection. METHODS: We conducted a retrospective cohort study that assessed prospectively collected data of all patients who were admitted between May and December 2020 to the Universal COVID-19 treatment center (UCTC), Khartoum, Sudan. UCTC compiled demographic, clinical, laboratory (including testing for malaria), and outcome data in all patients with confirmed COVID-19 hospitalized at that clinic. The primary outcome was all-cause mortality during the hospital stay. We built proportional hazard Cox models with malaria status as the main exposure and stepwise adjustment for age, sex, cardiovascular comorbidities, diabetes, and hypertension. RESULTS: We included 591 patients with confirmed COVID-19 diagnosis who were also tested for malaria. Mean (SD) age was 58 (16.2) years, 446/591 (75.5%) were males. Malaria was diagnosed in 270/591 (45.7%) patients. Most malaria patients were infected by Plasmodium falciparum (140/270; 51.9%), while 121/270 (44.8%) were coinfected with Plasmodium falciparum and Plasmodium vivax. Median follow-up was 29 days. Crude mortality rates were 10.71 and 5.87 per 1000 person-days for patients with and without concurrent malaria, respectively. In the fully adjusted Cox model, patients with concurrent malaria and COVID-19 had a greater mortality risk (hazard ratio 1.43, 95% confidence interval 1.21-1.69). DISCUSSION: Coinfection with COVID-19 and malaria is associated with increased all-cause in-hospital mortality compared to monoinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
引用
- Hussein R, Guedes M, Ibraheim N, et al. Impact of COVID-19 and malaria coinfection on clinical outcomes: a retrospective cohort study. Clin Microbiol Infect. 2022. PMID: 35367364. doi:10.1016/j.cmi.2022.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。